Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2146 - Association Between Immune-Related Adverse Events (irAEs) and Atezolizumab Efficacy in Advanced NSCLC: Analyses From the Ph III Study OAK

Date

09 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  Supportive Care and Symptom Management;  Immunotherapy;  Non-Small Cell Lung Cancer

Presenters

Joachim von Pawel

Citation

Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380

Authors

J. von Pawel1, K. Syrigos2, J. Mazieres3, D. Cortinovis4, R. Dziadziuszko5, D.R. Gandara6, P. Conkling7, J. Goldschmidt8, C.A. Thomas9, R. Bordoni10, M. Kosty11, F.S. Braiteh12, S. Hu13, M. Ballinger14, H. Patel15, M. Gandhi16, L. Fehrenbacher17

Author affiliations

  • 1 Medical Oncoloy, Asklepios-Fachklinikum, 82131 - Gauting/DE
  • 2 3rd Department Of Medicine, Athens School of Medicine, Athens/GR
  • 3 Thoracic Oncology, Toulouse University Hospital, Toulouse/FR
  • 4 Medical Oncology Unit, AOU San Gerardo, Monza/IT
  • 5 Department Of Oncology And Radiotherapy, Medical University of Gdansk, Gdansk/PL
  • 6 Thoracic Oncology, UC Davis Comprehensive Cancer Center, Sacramento/US
  • 7 Medical Oncoloy, Virginia Oncology Associates, Norfolk/US
  • 8 Clinical Research, Blue Ridge Cancer Care, Blacksburg/US
  • 9 Medical Oncoloy, New England Cancer Specialists, Scarborough/US
  • 10 Medicine, Georgia Cancer Specialists; Northside Hospital Cancer Institute, Atlanta/US
  • 11 Division Of Hematology/oncology, Scripps Clinic, La Jolla/US
  • 12 Medical Oncology, Comprehensive Cancer Centers of Nevada, 89169 - Las Vegas/US
  • 13 Biostatistics, Genentech, Inc., South San Francisco/US
  • 14 Product Development Oncology, Genentech, South San Francisco/US
  • 15 Product Development Safety Science, Genentech, South San Francisco/US
  • 16 Usma, Genentech, South San Francisco/US
  • 17 Oncology, Kaiser Permanente Medical Center, Vallejo/US
More

Resources

Abstract 2146

Background

OAK, the first randomized Ph III study of atezolizumab (atezo; anti–PD-L1), demonstrated a superior survival benefit with atezo vs docetaxel (doc) in NSCLC patients (pts) who had failed prior platinum therapy (HR 0.73; 95% CI: 0.62, 0.87). This analysis evaluates the benefit of atezo in pts with and without irAEs from the primary efficacy population (n = 850) of OAK. Safety data are reported separately.

Methods

Pts were randomized 1:1 to atezo (1200 mg) or doc (75 mg/m2) IV q3w. irAEs were defined using MedDRA Preferred Terms that included both diagnosed immune conditions and signs and symptoms potentially representative of immune related events, regardless of investigator-assessed causality. For this analysis, efficacy was evaluated in pts with and without irAEs in the atezo and doc arms; efficacy endpoints were OS, PFS and ORR. To overcome the inherent survivor bias between irAE subgroups (pts surviving longer may be more likely to have irAEs), OS was evaluated using a time-dependent (TD) Cox model. Additional exploratory analyses included atezo efficacy in pts who did vs did not receive systemic steroids for irAEs. Data cutoff: July 7, 2016.

Results

The incidence of irAEs in the atezo arm was 31% (25.0% grade 1-2, 6.2% grade 3-4, no grade 5). Baseline characteristics including PD-L1 expression on tumor cells or tumor-infiltrating immune cells were generally similar between irAE subgroups. OS per TD Cox model was in favor of atezo arm pts with irAEs vs those without irAEs (HR 0.79; 95% CI: 0.60, 1.05). Median time to onset of first irAE was 1.6 mo; post irAE mOS was 17.3 mo (95% CI: 11.7, 21.2). 24 atezo arm pts (6%) required corticosteroid treatment. Median OS in pts who did vs did not receive corticosteroids was 16.0 mo (95% CI: 10.3, 23.5; n = 24) vs 21.9 mo (95% CI: 16.6, NE; n = 106), respectively. Median PFS was 5.9 mo (95% CI: 2.6, 14.5) vs 5.4 mo (95% CI: 4.2, 8.8) and ORR was 29% (95% CI: 13, 51) vs 21% (95% CI: 13, 30) in pts who did vs did not receive corticosteroids.

Conclusions

In this analysis, irAEs did not negatively impact the survival benefit of atezo. Further investigation on the impact of corticosteroids on atezo efficacy in randomized trials is needed.

Clinical trial identification

NCT02008227

Legal entity responsible for the study

F. Hoffmann - La Roche Ltd.

Funding

F. Hoffmann - La Roche Ltd.

Disclosure

J. von Pawel: Adboard: AbbVie, Pfizer, Bristol Myers Squibb, Novartis money paid to the institution. D. Cortinovis: Membership for AB for Roche, Novartis, MSD, BI. R. Dziadziuszko: Honoraria or consulting fees from Roche, Pfizer, Boehringer‐Ingelheim, Clovis Oncology, Novartis, Astra‐Zeneca, Tesaro. D.R. Gandara: Consultant: Genentech Clinical trial grant: Genentech. P. Conkling: Research funding is US Oncology Research. J. Goldschmidt: Honoraria: Amgen Consulting/Advisory Role: Amgen Speakers Bureau: Bristol Myers‐Squibb, Celgene. M. Kosty: Support limited to Institutional support for the reported trial and other clinical trials. No direct compensation to investigator. F.S. Braiteh: COI: speaking and consulting fees received from Genentech. S. Hu: Genentech employee and Roche stock. M. Ballinger: Employee of Genentech, Roche stock. H. Patel: Genentech Employee. M. Gandhi: Employee of Genentech. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.